Abbott Laboratories (ABT)
| Market Cap | 196.83B |
| Revenue (ttm) | 41.22B |
| Net Income (ttm) | 5.74B |
| Shares Out | 1.73B |
| EPS (ttm) | 3.29 |
| PE Ratio | 34.49 |
| Forward PE | 22.46 |
| Dividend | $2.36 (2.08%) |
| Ex-Dividend Date | Jan 15, 2025 |
| Volume | 5,420,099 |
| Open | 113.62 |
| Previous Close | 113.91 |
| Day's Range | 113.39 - 114.79 |
| 52-Week Range | 99.71 - 121.64 |
| Beta | 0.73 |
| Analysts | Buy |
| Price Target | 129.80 (+14.38%) |
| Earnings Date | Jan 22, 2025 |
About ABT
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism,... [Read more]
Financial Performance
In 2023, Abbott Laboratories's revenue was $40.11 billion, a decrease of -8.12% compared to the previous year's $43.65 billion. Earnings were $5.70 billion, a decrease of -17.44%.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for ABT stock is "Buy." The 12-month stock price forecast is $129.8, which is an increase of 14.38% from the latest price.
News
Abbott pushes toddler milks that can cause health issues: lawsuit
The lawsuit accuses the formula maker of deceptively marketing the milks to make them seem like the next recommended step for toddlers.
The Near-Perfect Dividend Portfolio With 10 Sleep-Well-At-Night Gems
In a challenging market marked by uncertainty, building a resilient portfolio is key to long-term financial stability and peace of mind. Sleep-well-at-night, or SWAN, stocks are key. These reliable di...
Long-term possibilities in healthcare are unbelievable, says Jim Cramer
'Mad Money' host Jim Cramer looks at several healthcare stocks and shares his perspective on their trajectory in 2025.
Abbott Laboratories Q4 2024 Earnings Preview
Abbott Laboratories will report earnings pre-market on January 22, with an earnings consensus of $1.04 per share. Abbott continues to execute growth businesses with excellent marketing and distributio...
Healthcare has 'been so bad, maybe it's gonna be good' in 2025, says Mizuho's Jared Holz
Jared Holz, Mizuho Securities America healthcare sector strategist, joins CNBC's 'Squawk on the Street' to discuss outlooks on the healthcare sector in the new year
Abbott Hosts Conference Call for Fourth-Quarter Earnings
ABBOTT PARK, Ill., Jan. 2, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its fourth-quarter 2024 financial results on Wednesday, Jan. 22, before the market opens.
My New Year's Resolution For 2025: Invest $10,000 In These 6 Stocks
I review here the stocks of six quality companies that I am convinced will bring me closer to my ambitious goal of being able to fund my living expenses through dividends. Dividend growth investing is...
Highest Quality Dividend Kings For 2025
Only 11 Dividend Kings outperformed the S&P 500 during the last decade based on Total Return. 5 Dividend Kings earn the rank of "High Quality" based on my custom quantitative model. Using a variation ...
DexCom, Abbott Agree to Settlement in Patent Litigation
The companies have been involved in global patent litigation, with both having accused the other of infringing certain patents, and each has filed counterclaims and actions to invalidate the other par...
Abbott and DexCom settle glucose monitor patent disputes
Abbott Laboratories said on Monday it and DexCom have reached an agreement to settle all patent disputes between the companies related to continuous glucose monitoring devices.
Abbott Laboratories: A Future-Driven Pharma Brand With A Robust Pipeline
My initial rating of Abbott Laboratories is a buy, agreeing with today's Wall Street consensus. The future growth indicators, diversified portfolio across many clinical segments, and leading roles in ...
Abbott Announces First-in-World Leadless Pacing Procedures in the Left Bundle Branch Area of the Heart
Abbott's investigational AVEIR™ Conduction System Pacing (CSP) leadless pacemaker system is specifically designed to deliver pacing to the left bundle branch area, activating the heart's natural condu...
Best Way To Invest $100,000: Build An 8-Stock Portfolio For Growth And Value
Concentrate on a select few high-conviction stocks across different sectors to avoid "diworsification" and maximize returns, inspired by Charlie Munger and Warren Buffett. Utilize Joel Greenblatt's "M...
Abbott Increases Quarterly Dividend for 53rd Consecutive Year
Dividend increased by 7.3% Quarterly dividend payout has increased more than 60% since 2020 404th consecutive quarterly dividend to be paid by Abbott since 1924 ABBOTT PARK, Ill., Dec. 13, 2024 /PRNew...
University of Nebraska Wins the Abbott and Big Ten Conference's Nationwide 'We Give Blood Drive' Competition, Receives $1 Million Grant from Abbott
Nearly 20,000 Big Ten students, alumni and fans across the country donated blood as part of the Abbott-Big Ten nationwide competition this college football season, helping save as many as 60,000 lives...
Abbott Announces First Step Toward Its Software-Guided Balloon-Expandable TAVI System to Treat Aortic Stenosis
The investigational transcatheter aortic valve implantation (TAVI) system will complement Abbott's Navitor™ TAVI system for aortic stenosis, a common and life-threatening heart valve disease The inves...
Abbott Laboratories: Investors Should Wait For A Pullback
Abbott has a very stable gross profit margin, while the company's revenue and return on invested capital could be more consistent. The company has increased their dividend for more than 50 years and s...
MACH Alliance Expands Education Program, Appoints Dylan Valade of Abbott As Head of Education
NEW YORK--(BUSINESS WIRE)--MACH Alliance, a not-for-profit industry body dedicated to advocating for open, best-of-breed technology ecosystems, today announced the expansion of its thriving education ...
Abbott India posts Q2 profit rise on strong demand, price hikes
Drugmaker Abbott India reported a rise in second-quarter profit on Thursday, helped by strong demand for its gastrointestinal and anti-infective medications.
The lawsuits against Abbott 'really steam me', says Jim Cramer
'Mad Money' host Jim Cramer takes a closer look at the litigation facing Abbott Labs.
Jim Cramer takes a closer looks at the litigation facing Abbott and what it means for the company
'Mad Money' host Jim Cramer takes a closer look at the litigation facing Abbott Labs.
Abbott, Reckitt Stocks Gain as Baby Formula Makers Score Rare Legal Win
Shares of Abbott Laboratories (ABT) are rising and those of Reckitt Benckiser are gaining in London trading Friday, a day after a jury cleared the two infant formula makers of liability for a boy's de...
Abbott shares rise after securing first win in premature infant formula trial
Abbott Laboratories shares rose nearly 5% before the bell on Friday, after a jury cleared the company and a Reckitt unit of liability in a lawsuit over their premature baby formulas' risks.
Abbott Labs and Reckitt Benckiser shares surge on court's baby formula ruling
A court in St. Louis, Missouri ruled in favor of Abbott Laboratories and Reckitt Benckiser over claims their specialized baby formula caused users to develop a bowel disease called NEC